Soleno Therapeutics (SLNO) Competitors $50.05 -0.09 (-0.18%) Closing price 04:00 PM EasternExtended Trading$51.20 +1.16 (+2.31%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. STVN, GKOS, BLCO, INSP, NARI, IRTC, PRCT, NVST, TMDX, and LIVNShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Envista (NVST), TransMedics Group (TMDX), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. Soleno Therapeutics vs. Stevanato Group Glaukos Bausch + Lomb Inspire Medical Systems Inari Medical iRhythm Technologies PROCEPT BioRobotics Envista TransMedics Group LivaNova Stevanato Group (NYSE:STVN) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability. Do analysts prefer STVN or SLNO? Soleno Therapeutics has a consensus price target of $71.20, suggesting a potential upside of 42.26%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Does the media refer more to STVN or SLNO? In the previous week, Stevanato Group had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 8 mentions for Stevanato Group and 6 mentions for Soleno Therapeutics. Stevanato Group's average media sentiment score of 1.21 beat Soleno Therapeutics' score of 1.14 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of STVN or SLNO? 97.4% of Soleno Therapeutics shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by company insiders. Comparatively, 12.3% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, STVN or SLNO? Stevanato Group has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.7, indicating that its share price is 270% less volatile than the S&P 500. Does the MarketBeat Community favor STVN or SLNO? Soleno Therapeutics received 283 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 72.29% of users gave Soleno Therapeutics an outperform vote while only 62.50% of users gave Stevanato Group an outperform vote. CompanyUnderperformOutperformStevanato GroupOutperform Votes3062.50% Underperform Votes1837.50% Soleno TherapeuticsOutperform Votes31372.29% Underperform Votes12027.71% Which has preferable earnings & valuation, STVN or SLNO? Stevanato Group has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStevanato Group$1.10B5.83$157.62M$0.4844.29Soleno TherapeuticsN/AN/A-$38.99M-$4.26-11.75 Is STVN or SLNO more profitable? Stevanato Group has a net margin of 10.47% compared to Soleno Therapeutics' net margin of 0.00%. Stevanato Group's return on equity of 9.86% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stevanato Group10.47% 9.86% 5.79% Soleno Therapeutics N/A -61.99%-55.21% SummaryStevanato Group beats Soleno Therapeutics on 10 of the 17 factors compared between the two stocks. Remove Ads Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.30B$3.24B$5.68B$8.32BDividend YieldN/A1.61%4.55%4.02%P/E Ratio-15.0815.1124.5519.25Price / SalesN/A41.88395.7294.09Price / CashN/A44.0938.1634.64Price / Book9.703.407.064.46Net Income-$38.99M$89.74M$3.19B$247.07M7 Day Performance-0.12%0.88%1.49%3.05%1 Month Performance11.57%-8.82%5.87%-2.85%1 Year Performance20.11%-10.12%14.94%4.63% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.4317 of 5 stars$50.05-0.2%$71.20+42.3%+19.4%$2.30BN/A-15.0830High Trading VolumeSTVNStevanato Group1.6585 of 5 stars€20.71+3.4%N/A-28.0%$6.27B$1.10B44.065,635Positive NewsGKOSGlaukos4.5395 of 5 stars$103.12+0.9%$163.25+58.3%+22.3%$5.83B$383.48M-35.93780Positive NewsBLCOBausch + Lomb3.7682 of 5 stars$15.39+0.3%$20.00+29.9%-1.6%$5.43B$4.79B-16.9212,500News CoverageINSPInspire Medical Systems4.7036 of 5 stars$166.59+2.7%$228.82+37.4%-13.4%$4.94B$802.80M96.291,246Positive NewsNARIInari Medical0.936 of 5 stars$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800IRTCiRhythm Technologies1.5315 of 5 stars$103.70+3.0%$119.73+15.5%-2.3%$3.26B$591.84M-28.491,790Positive NewsGap UpPRCTPROCEPT BioRobotics3.0601 of 5 stars$59.03+2.4%$94.29+59.7%+27.8%$3.24B$224.50M-30.27430News CoverageNVSTEnvista4.1292 of 5 stars$17.16+3.0%$20.18+17.6%-17.9%$2.95B$2.51B-2.6412,700TMDXTransMedics Group3.051 of 5 stars$67.69-1.2%$122.70+81.3%+0.9%$2.28B$441.54M72.01210LIVNLivaNova4.2276 of 5 stars$41.41+5.5%$61.17+47.7%-27.9%$2.25B$1.25B98.602,900Positive News Remove Ads Related Companies and Tools Related Companies Stevanato Group Alternatives Glaukos Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives Inari Medical Alternatives iRhythm Technologies Alternatives PROCEPT BioRobotics Alternatives Envista Alternatives TransMedics Group Alternatives LivaNova Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLNO Stock Free SLNO Stock Alerts